Size | Price | |
---|---|---|
100mg | ||
250mg | ||
500mg |
ln Vitro |
In Ramos cells and CLL or chemotherapeutic lines, ulocliplumab (0-100 μM; 48 h) is effective in inducing CXCR4 binding, but it lacks complement (CDC) or antibody-dependent cellular cytotoxicity (ADCC); in contrast, ulocliplumab (0.2 μM, 2 μM; 15 s) inhibits F-actin aggregation and lowers the peak response to CXCL12 (20 nM-2 μM; 1 h). Programmed cell death (PCD) can be induced by ulocliplumab (200 nM; 6 h) without the need for caspase [1]. In Ramos, ulocoplumab (10 μg/mL; 4 h) suppresses the calcium ionization in CLL cells produced by CXCL12, with an EC50 of 10 nM [2].
|
---|---|
ln Vivo |
Ulocplumab (3–30 mg/kg; intraperitoneally; 5 doses over 3–4 days; total of 65 days) luminous probe Growth of tumors in various myeloma xenograft models, such as HL-60 cellsand Ramos B cells
|
Cell Assay |
Apoptosis analysis[1]
Cell Types: Ramos cells and primary leukemia cells (from CLL) Tested Concentrations: 0-100 μM Incubation Duration: 48 hrs (hours) Experimental Results: Induced apoptosis in Ramos cells with an IC50 value of 1.9 nM and in CLL It was shown to be pro-apoptotic in the patient's primary leukemia cells with an IC50 value of 12.43 nM. |
Animal Protocol |
Animal/Disease Models: Severe combined immunodeficiency (SCID) mouse AML model (MOLP-8 cells) [1]
Doses: 3-30 mg, tumor model of MOLP-8 cells, Nomo-1 cells and JJN-3R cells [1]. /kg Doses: intraperitoneal (ip) injection; every 3-4 days for 5 doses; continued for 65 days Experimental Results: Mean tumor growth was Dramatically delayed by 66% and 56% compared to isotype controls on day 25. |
References |
[1]. Kashyap MK, et al. Ulocuplumab (BMS-936564 / MDX1338): a fully human anti-CXCR4 antibody induces cell death in chronic lymphocytic leukemia mediated through a reactive oxygen species-dependent pathway. Oncotarget. 2016 Jan 19;7(3):2809-22.
[2]. Kuhne MR, et al. BMS-936564/MDX-1338: a fully human anti-CXCR4 antibody induces apoptosis in vitro and shows antitumor activity in vivo in hematologic malignancies. Clin Cancer Res. 2013 Jan 15;19(2):357-66. |
Molecular Weight |
146.2 (kDa)
|
---|---|
CAS # |
1375830-34-4
|
Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
Solubility (In Vivo) |
Note: Listed below are some common formulations that may be used to formulate products with low water solubility (e.g. < 1 mg/mL), you may test these formulations using a minute amount of products to avoid loss of samples.
Injection Formulations
Injection Formulation 1: DMSO : Tween 80: Saline = 10 : 5 : 85 (i.e. 100 μL DMSO stock solution → 50 μL Tween 80 → 850 μL Saline)(e.g. IP/IV/IM/SC) *Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH ₂ O to obtain a clear solution. Injection Formulation 2: DMSO : PEG300 :Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL DMSO → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline) Injection Formulation 3: DMSO : Corn oil = 10 : 90 (i.e. 100 μL DMSO → 900 μL Corn oil) Example: Take the Injection Formulation 3 (DMSO : Corn oil = 10 : 90) as an example, if 1 mL of 2.5 mg/mL working solution is to be prepared, you can take 100 μL 25 mg/mL DMSO stock solution and add to 900 μL corn oil, mix well to obtain a clear or suspension solution (2.5 mg/mL, ready for use in animals). View More
Injection Formulation 4: DMSO : 20% SBE-β-CD in saline = 10 : 90 [i.e. 100 μL DMSO → 900 μL (20% SBE-β-CD in saline)] Oral Formulations
Oral Formulation 1: Suspend in 0.5% CMC Na (carboxymethylcellulose sodium) Oral Formulation 2: Suspend in 0.5% Carboxymethyl cellulose Example: Take the Oral Formulation 1 (Suspend in 0.5% CMC Na) as an example, if 100 mL of 2.5 mg/mL working solution is to be prepared, you can first prepare 0.5% CMC Na solution by measuring 0.5 g CMC Na and dissolve it in 100 mL ddH2O to obtain a clear solution; then add 250 mg of the product to 100 mL 0.5% CMC Na solution, to make the suspension solution (2.5 mg/mL, ready for use in animals). View More
Oral Formulation 3: Dissolved in PEG400  (Please use freshly prepared in vivo formulations for optimal results.) |
---|
Calculation results
Working concentration: mg/mL;
Method for preparing DMSO stock solution: mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation::Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O,mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.